Skip to main content
. 2022 Oct 17;12:17397. doi: 10.1038/s41598-022-22449-w

Table 1.

Baseline demographics of the patients.

Maintained weight* (n = 161, 74.9%) Reduced weight** (n = 54, 25.1%) P-value
Age (years) 71.2 ± 7.2 73.8 ± 7.7 0.032
Sex
Male 134 (83.2%) 41 (75.9%) 0.233
Female 27 (16.8%) 13 (24.1%)
BMI (kg/m2) 24.4 ± 2.9 23.0 ± 2.9 0.002
Baseline body weight (kg) 65.3 ± 9.3 60.1 ± 9.0  < 0.001
Smoking history
Never smoker 35 (21.7%) 11 (20.4%) 0.692
Ever smoker 126 (78.3%) 43 (79.6%)
Comorbidities
Hypertension 48 (29.8%) 12 (22.2%) 0.282
Diabetes mellitus 41 (25.5%) 12 (22.2%) 0.635
COPD 21 (13.0%) 2 (3.7%) 0.055
Malignancy 23 (14.3%) 3 (5.6%) 0.089
Pulmonary function test
FVC (% of predicted) 81.1 ± 15.5 71.1 ± 16.8  < 0.001
DLCO (% of predicted) 72.0 ± 20.5 62.3 ± 20.7 0.004
Pirfenidone treatment
Dose adjustment 56 (34.8%) 19 (35.2%) 0.957

Data are expressed as mean ± standard deviation or counts (%).

BMI body mass index, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, COPD chronic obstructive pulmonary disease.

*Maintained weight group is weight gain or weight loss < 5%/year, **Reduced weight group is weight loss ≥ 5%/year.